Coherus Oncology Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Coherus Oncology, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue266.96257.24211.04326.55475.82356.100.00
Cost of Revenue117.55158.9970.0857.5937.6717.080.00
Gross Profit149.4198.25140.96268.96438.16339.020.00
Operating Expenses
Research & Development93.34109.44199.36363.11142.7694.19110.24
Selling, General & Administrative150.44192.02198.48169.71139.08137.0494.18
Operating Expenses243.77301.45397.84532.82281.84231.23204.42
Operating Income-94.37-203.20-256.88-263.86156.32107.77-204.42
Other Income/Expense
Interest Income4.502.801.901.400.600.000.00
Interest Expense-27.16-40.54-32.4722.96-21.170.009.68
Other Income/Expense-1.13-5.47-2.400.28-0.55-2.614.69
Income
Income Before Tax28.51-238.27-291.75-287.10135.7192.78-209.41
Income Tax Expense0.00-0.380.000.003.462.900.00
Net Income28.51-237.89-291.75-287.10132.2489.83-209.34
Net Income - Continuous Operations28.51-237.89-291.75-287.100.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-89.09-191.53-255.58-260.69159.76115.85-196.49
EBIT-94.37-197.73-259.28-264.14156.87110.38-199.73
Depreciation & Amortization5.283.203.603.502.903.260.00
Earnings Per Share
Basic EPS--3.00-4.00-4.002.001.00-3.00
Diluted EPS--3.00-4.00-4.002.001.00-3.00
Basic Shares Outstanding114.5594.1677.6375.4571.4169.6865.03
Diluted Shares Outstanding114.8394.1677.6375.4583.4973.1965.03